Notice of Launching Urine Tumor Marker
Assay Kit
|
|
|
| |
|
We hereby announce that TRANS GENIC INC. (hereinafter
referred to as q�weq�) released Urinary Diacetylspermidine ELISA
Kit developed by GANP®Mouse Technology (*1) as a research reagent
on October 3, 2007.
|
|
Polyamines (*2) excreted in urine have attracted attention since
they are considered to be used as tumor markers (*3). We have
especially focused on diacetylspermine and diacetylspermidine
among them in our research and development for assay system using
specific antibodies.
Regarding diacetylspermidine, it has been difficult to produce specific antibodies
with conventional methods, but we are successfully producing highly specific
antibodies using GANP®Mouse Technology. (Open patent number: 2006-106992)
We have recently succeeded in developing an assay system using the antibody and
prepared to release it as an assay kit.
q_q_The following is the summary of the launch of the kit.
Product Name |
Urinary Diacetylspermidine
ELISA Kit (Code KK123) |
Specification |
80 assays |
Price |
105,000 yen (consumption tax
included) |
Distribution method |
Sold through our distributing
agents
Cosmo Bio Co., Ltd.,
Funakoshi Corporation,
Wako Pure Chemical Industries, Ltd. |
Annual Sales Prospect |
50 - 100 kits |
Characteristics and practicality of this product and
usefulness of the product as a urine tumor marker were presented
by TRANS GENIC and Dr. Seiji Hosaka of National Hospital Organization
Kumamoto Medical Center, respectively, at the 66th Annual Meeting
of the Japanese Cancer Association on October 3, 2007. (*4)
Regarding diacetylspermine whose assay kit has already
been on the market, we have onerously provided several diagnostic
reagent manufacturers with the monoclonal antibody and licensed
the patent (patent number: 3816512). They are now developing diagnostic
regents utilizing the antibody.
Besides developing diagnostic reagents, we are distributing
antibodies and ELISA kits as research reagents to support advancement
of life-science such as researches on proteins and identification
of causes of various diseases. We will continuously make our efforts
to develop new antibody reagents utilizing our unique GANP®Mouse
Technology and DNA immunization (*5) in order to enhance our product
lineups in the area of cancer and metabolic syndrome.
The effects of the launch of the product on our business
performance are as yet unknown, but we will make an announcement
as soon as it is revealed to have a significant impact on our future
performance.
Reference:
Overview of business using GANP®Mouse
Technology (*1)
qﾎ.
Commercialization (as of the end of August, 2007)
|
1-1 |
Number
of research reagents launched: 4
|
1-2 |
Number of licensing we have granted
for developing diagnostic reagents: 3 |
| |
| qﾏ. Number of custom
production service of antibodies: 62 (as of the end of August,
2007) |
| |
|
Overview of development of tumor marker using urine
qﾎ.
Diacetylspermine
|
1-1 |
qⅡrinary Diacetylspermine ELISA Kitq� was released as a
research reagent in October, 2003.
|
1-2 |
Usefulness of diacetylspermine
to develop diagnostic reagents has been examined by several
diagnostic reagent manufacturers. We have licensed one of
them. |
| |
| qﾏ. Diacetylspermidine |
2-1 |
qⅡrinary Diacetylspermidine ELISA
Kitq� was released as a research reagent in October, 2007. |
Note:
|
|
*1 |
GANP®Mouse Technology
This is our unique technology to produce antibodies using q⑧ANP® miceq�,
genetically engineered mice whose GANP gene expression is increased. Compared
to conventional methods of antibody production, GANP®Mouse Technology can
produce higher-affinity and higher-specificity antibodies with a higher success
rate. Therefore it is considered that the technology has many advantages in applying
it to development of diagnostic reagents and pharmaceuticals.
We regard it as a fundamental technology in our antibody-related technological
platforms and promote various businesses utilizing it. For example, we are developing
our original products, offering custom production services and granting its license
to pharmaceutical companies and diagnostic reagent manufacturers to gain profits
from its licensing fees and product royalties.
- What is GANP (Germinal Center Associated Nuclear Protein)?
It is a new nuclear factor increasingly expressed in germinal-center B cells.
Dr. Nobuo Sakaguchi of Kumamoto University discovered it.
- What are characteristics of GANP®mice?
Expression of GANP genes in germinal-center B cells is more increased in GANP
mice than in normal mice. These GANP proteins cause the genetic alteration
of the V regions with increased mutations. Therefore high-affinity and high-specificity
antibodies can be produced with a high success rate.
Sakaguchi N. et al., J Immunol. 2005 Apr 15;174(8):4485-94.
|
|
*2
|
Polyamine
They are substances considered to play an important role
in the process of cell growth and control. After finished
playing the role, they are excreted from cells and eventually
in urine.
|
|
*3
|
Tumor Markers
They are substances detected in body fluids such as blood and urine, or
tissues in response to cancer growth.
|
|
*4
|
Topics presented at the 66th Annual Meeting
of the Japanese Cancer Association
> q⑤eveloping a competitive ELISA method using a highly
specific antibody for N1 and N8-diacetylspermidine as a
new tumor marker in urineq�
Shingo Shinagawa 1, Hiroshi Nose 1, Akemi Matsuoka 1, Junko Kono 1, Seiji Hosaka
2
(1 TRANS GENIC INC., 2 Surgical Department, National Hospital Organization
Kumamoto Medical Center)
>q④onfirming usefulness of diacetylspermidine (DiAcSpd)
in urine as markers of various tumors using a new ELISA
kitq�
Seiji Hosaka 1, Shingo Shinagawa 2, Hiroshi Nose 2, Akemi Matsuoka 2, Junko
Kono 2, Kenichiro Yamamoto 1, Naoya Yoshida 1, Shinichiro Tanaka 1, Masaharu
Odo 1, Takashi Kurisaki 1,
Yasuharu Nishimura 3 , Shigeru Katafuchi 1, Satoshi Ikei 1
(1 Surgical Department, National Hospital Organization Kumamoto Medical Center,
2 TRANS GENIC INC., 3 Department of Immunogenetics, Faculty of Medical and
Pharmaceutical Sciences, Kumamoto University)
|
|
*5
|
DNA immunization
Unlike a commonly practiced antibody production method in which
protein or peptides are used as antigens, expression vectors
which encode objective proteins are directly injected in animals
in DNA immunization. Therefore, the antigens easily retain
their original structures in vivo, enabling us to produce antibodies
which have been difficult to produce by conventional methods,
such as an antibody which recognizes membrane proteins.
|
|
| |
| |
|
